Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Harvard Business School
McKinsey
Johnson and Johnson
Baxter

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR GILENYA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Gilenya

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00670449 ↗ An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis Completed Mitsubishi Tanabe Pharma Corporation Phase 2 2008-04-01 This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis.
NCT00670449 ↗ An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis Completed Novartis Phase 2 2008-04-01 This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis.
NCT01285479 ↗ The Gilenya Pregnancy Registry Recruiting Novartis Pharmaceuticals 2011-10-15 The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to Gilenya before (up to 8 weeks before last menstrual period) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations.
NCT01466114 ↗ Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Recruiting Synthetic Biologics (formerly Adeona Pharmaceuticals) Phase 2 2011-10-01 Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as compared to treatment with a placebo pill in combination with standard anti-inflammatory drugs in women with MS.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gilenya

Condition Name

Condition Name for Gilenya
Intervention Trials
Multiple Sclerosis 9
Relapsing Remitting Multiple Sclerosis 5
Relapsing-Remitting Multiple Sclerosis 2
Inflammation 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gilenya
Intervention Trials
Multiple Sclerosis 20
Sclerosis 19
Multiple Sclerosis, Relapsing-Remitting 12
Stroke 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gilenya

Trials by Country

Trials by Country for Gilenya
Location Trials
United States 83
Canada 12
China 10
Brazil 8
Italy 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gilenya
Location Trials
Texas 6
Colorado 5
California 5
Ohio 4
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gilenya

Clinical Trial Phase

Clinical Trial Phase for Gilenya
Clinical Trial Phase Trials
Phase 4 11
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gilenya
Clinical Trial Phase Trials
Completed 14
Recruiting 6
Terminated 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gilenya

Sponsor Name

Sponsor Name for Gilenya
Sponsor Trials
Novartis Pharmaceuticals 8
Novartis 5
Huzhou Center Hospital 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gilenya
Sponsor Trials
Other 43
Industry 20
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Dow
Baxter
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.